Chao Hong Hu
Geen lopende functies
Vermogen: 96 M $ op 30-04-2024
Profiel
Chao Hong Hu was the founder and the Chairman & General Manager of Shanghai Miracogen, Inc., which was founded in 2014.
Dr. Hu also held the position of Co-Chief Executive Officer & Executive Director at Lepu Biopharma Co., Ltd.
from 2020 to 2024.
Prior to that, Dr. Hu worked as the Director-Molecular Biology & Clinical Immunology at ID Biomedical Corp.
Dr. Hu also served as the Director-Bioassay Development & Process Analytics at Seagen Inc. from 2007 to 2013, and as the Head-Molecular Biology & Clinical Immunology at GSK Plc in 2006.
Dr. Hu obtained an undergraduate degree from Wuhan University in 1986.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
15-12-2023 | 136 355 106 ( 8.49% ) | 96 M $ | 30-04-2024 |
Eerdere bekende functies van Chao Hong Hu
Bedrijven | Functie | Einde |
---|---|---|
LEPU BIOPHARMA CO., LTD. | Chief Executive Officer | 31-01-2024 |
SEAGEN INC. | Corporate Officer/Principal | 01-10-2013 |
GSK PLC | Corporate Officer/Principal | 01-05-2007 |
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | 01-01-2005 |
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Part of Lepu Biopharma Co., Ltd., Shanghai Miracogen, Inc. is a Chinese company that engages in the development, clinical research, and industrialization of cancer targeted therapy drugs. The private company is based in Pudong, China. The company was founded in 2014 by Chao Hong Hu and Marry Hu. Marry Hu has been the CEO since 2014. | Chief Executive Officer | - |
Opleiding van Chao Hong Hu
Wuhan University | Undergraduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
GSK PLC | Health Technology |
LEPU BIOPHARMA CO., LTD. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
ID Biomedical Corp.
ID Biomedical Corp. Medical SpecialtiesHealth Technology ID Biomedical Corp. develops gene-based disease testing and subunit vaccines. It conducts research, development, manufacturing, sales, and marketing from its facilities in Canada and in the United States. The company was founded in 1991 and is headquartered in Vancouver, Canada. | Health Technology |
Seagen Inc.
Seagen Inc. Pharmaceuticals: MajorHealth Technology Seagen Inc. is a biotechnology company, which engages in the development and commercialization of targeted therapies for the treatment of cancer. It also focuses on the advancement of therapies for solid tumors and blood-related cancers. Its products include Adcetris, Padcev, Tivdak, and Tukysa. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA. | Health Technology |
Shanghai Miracogen, Inc.
Shanghai Miracogen, Inc. BiotechnologyHealth Technology Part of Lepu Biopharma Co., Ltd., Shanghai Miracogen, Inc. is a Chinese company that engages in the development, clinical research, and industrialization of cancer targeted therapy drugs. The private company is based in Pudong, China. The company was founded in 2014 by Chao Hong Hu and Marry Hu. Marry Hu has been the CEO since 2014. | Health Technology |